Stifel Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $40
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Alex Thompson has initiated coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and a price target of $40.
August 09, 2023 | 9:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel has initiated coverage on RAPT Therapeutics with a Buy rating and a price target of $40, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Stifel's Buy rating and $40 price target for RAPT Therapeutics indicate a positive outlook for the company, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100